Frontage and Spaulding team on core lab services and China

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trial

Frontage Laboratories and Spaulding Clinical Research have teamed up to target China’s rapidly expanding contract research sector.

Under the collaboration, terms of which were not provided, Spaulding will perform the electrocardiographic studies required by Frontage’s clients at its facility in West Bend, Wisconsin.

Frontage spokesman Matt Harrington told that demand for centralised cardiac studies was the key driver for the partnership, citing a 2010 study by the Tufts Center for the Study of Drug Development (CSDD) as evidence.

“[According to the study] nearly 100 per cent of industry respondents believe central cardiac labs are accurate and efficient, yet only 33 per cent of all ECGs are collected centrally using a Core Lab, resulting in higher hidden costs​.”

Clearly, there is need right now for increased adoption of Centralized Cardiac Safety. While Frontage had considered developing its own capabilities to meet the need, it chose to partner with Spaulding Clinical to provide this service more rapidly and with the highest possible quality.”

Harrington added that increasing US Food and Drug Administration (FDA) requirements for data on QT prolongation are also driving pharmaceutical industry demand for this type of service.

In return, Pennsylvania-based Frontage will provide bioanalytical method development, sample processing, formulation and trial supply services for Spaulding.

Additionally, one of Frontage’s two sites in China, located in Zhengzhou and Changchun, will be available to will be available to Spaulding’s customers.


The partnership with Frontage fits with the expansion strategy Spaulding has employed in recent months. In late August​ the US firm teamed up with Biocon’s India-based unit Clinigene International in a deal focused on the latter firm’s BA/BE testing, lab and bioanalytical services offering.

A few weeks earlier Spaulding used a similar approach to boost its presence in Europe, forming a partnership with French contract research organisation Eurofins Optimed Clinical Research.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more